摘要:
The present invention provides for a proteomic approach to predicting, diagnosing and staging invasive bladder cancer, and for predicting patient survival and therapeutic efficacy. More specifically, the target being analyzed for reduced expression is FOXA1, and optionally including analysis of increased FOXA2 expression.
摘要:
The present invention relates to a novel algorithm that uses molecular profile signatures to extrapolate the physiological processes of one type of cell set (e.g., cell line, tissue, normal or diseased) to predict the activity of an agent or agents against another type of cell set that has never been exposed to the agent in question (drug efficacy prediction). The novel algorithm also allows one to predict the therapeutic response of a patient to a therapeutic regimen even though the patient (or patients) may have never been exposed to that agent before, thereby allowing for selecting a therapeutic agent or combination of agents that would best suit the patient (i.e., personalized medicine). The present invention also relates to methods of using the agents identified by the novel algorithm to treat a variety of diseases, including cancer.